Glenmark Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
4/10
|
41.74 | 45.74 | -8.76% | 19.17 | +117.69% |
| P/S |
|
2.31 | 5.12 | -55% |
|
|
| P/BV |
|
3.42 | 6.3 | -45.74% |
|
|
| P/FCF |
|
-18.99 | 168.72 | -111.26% |
|
|
| Ev/Ebitda |
|
8.37 | 13.54 | -38.19% |
|
|
| Ev/S |
|
1.32 | 4.77 | -72.4% |
|
|
| Ev/FCF |
|
-13.16 | 163.7 | -108.04% |
|
|
| E/P |
|
-0.0679 | 0.0451 | -250.51% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
5/10
|
15.72 | 20.29 | -22.5% | 17.46 | -9.94% |
| ROE |
|
-17.34 | 17.11 | -201.31% |
|
|
| ROA |
|
-8.9 | 10.34 | -186.15% |
|
|
| ROIC |
|
0 | 10.89 | -100% |
|
|
| ROS |
|
-12.91 | 11.98 | -207.72% |
|
|
| ROCE |
|
0 | 4.26 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
5/10
|
2.53 | 1.22 | 107.62% | 2.2 | +14.76% |
| Nеt Debt/Ebitda |
|
1.59 | 1.06 | 50.01% |
|
|
| Debt/Ratio |
|
0.3222 | 0.1307 | 146.54% |
|
|
| Debt/Equity |
|
1.1 | 0.7537 | 46.34% |
|
|
| Debt/Net Income |
|
-3.08 | 3.19 | -196.52% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0.35/10
|
0.1441 | 11.92 | -98.79% | 0.6325 | -77.22% |
| Number of years of dividend growth |
|
0 | 1.26 | -100% | ||
| DSI |
|
0.9286 | 0.8481 | 9.49% |
|
|
| Average dividend growth |
|
3.33 | -63.67 | -105.23% |
|
|
| Average percentage for 5 years |
|
0.6325 | 11.6 | -94.55% |
|
|
| Average percentage for payments |
|
13.01 | 30.57 | -57.45% |
|
|
| Difference from average difference in sector |
|
-11.77 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
2/10
|
9.35 | 80.84 | -88.43% | ||
| Growth impulse Ebitda in 5 years |
|
-14.48 | 45.31 | -131.96% | ||
| Growth impulse Net Income in 5 years |
|
-293.52 | 131.41 | -323.36% | ||
| Growth impulse FCF in 5 years |
|
-352.43 | 76.02 | -563.6% | ||
| Growth impulse EPS in 5 years |
|
-293.55 | 286.48 | -202.47% |
IP Score
3.59/10
